

DAFTAR PUSTAKA

- Abergel R.P., Pizzurro D., Meeker C.A., *et al.* 1985. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. *J Invest Dermatol.* 84:384-8.
- Ali S., Saeed S. 2011. Comparison of The Efficacy of Intralesional Triamcinolone Acetonide and 5-Fluorouracil Tattooing for The Treatment of Keloids. *Dermatol Surg.* 38 : 104-109.
- Alster T.S., Handrick C. 2000. Laser treatment of hypertrophic scars, keloids, and striae. *Semin Cutan Med Surg.* 19:287–292.
- Apikian M., Goodman G. 2004. Intralesional 5-fluorouracil in the treatment of keloid scars. *Australas J Dermatol.* 45:140–143.
- Atiyeh B.S. 2007. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. *Aesthetic Plast Surg.* 31:468–494.
- Bayat A., Arscott G., Ollier W.E.R. McGrouther D.A., Ferguson M.W.J. 2005. Keloid disease: Clinical relevance of single versus multiple site scars. *British Association of Plastic Surgeons.* 58:28-37.
- Berman B., Villa A.M., Ramirez C.C. 2005. Novel opportunities in the treatment and prevention of scarring. *J Cutan Med Surg.* 32-36.
- Berridge M.V., Tan A.S. 1993. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of

mitochondrial electron transport in MTT reduction. *Arch Biochem Biophys.* 303(2):474-482.

Boyadjiev C., Popchristova E., Mazgalova J. 1995. Histomorphologic changes in keloids treated with Kenacort. *J Trauma.* 38:299–302.

Butler P.D., Longaker M.T., Yang G.P. 2008. Current Progress in Keloid Research and Treatment. *J Am Coll Surg.* 206:731-741.

Calderon M., Lawrence W.T., Banes A. 1996. Increased Proliferation in Keloid Fibroblast Wounded *in vitro*. *J Surg Res.* 61:343-347.

Chen M.A., Davidson T.M. 2005. Scar management: prevention and treatment strategies. *Curr Opin Otolaryngol Head Neck Surg.* 13(4):242-247.

Clayman M.A., Clayman S.M., Mazingo D.W. 2006. The use of collagen-glycosaminoglycan copolymer (Integra) for repair of hypertrophic scars and keloids. *J Burn Care Res.* 27(3):404-409.

Davidson S., *et al.* 2009. A primary care perspective on keloids. *Medscape J Med.* 11(1):18.

Davison S.P., Dayan J.H., Clemens M.W., Sonni S., Wang A., Crane A. 2009. Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids. *Aesthet Surg J.* 29:40-46.

de Oliveira G.V., Nunes T.A., Magna L.A., Cintra M.L., Kitten G.T., Zarpellon S., *et al.* 2001. Silicone versus nonsilicone gel dressings: A controlled trial. *Dermatol Surg.* 27:721-726.

Fitzpatrick R.E. 1999. Treatment of inflamed hypertrophic scars using intralesional 5-FU. *Dermatol Surg.* 25:224–232.

Friedman D.W., Boyd C.D., Mackenzie J.W., Norton P., Olson R.M., Deak S.B.

1993. Regulation of collagen gene expression in keloids and hypertrophic scars. *J Surg Res.* 55:214-222.

Gauglitz G.G., Korting H.C., Pavicic T., Ruzicka T., Jeschke M.G. 2011.

Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategies. *Mol Med.* 17(1-2): 113-125.

Gira A.K., Brown L.F., Washington C.V., Cohen C., Arbiser J.L. 2004. Keloids

demonstrate high-level epidermal expression of vascular endothelial growth factor. *J Am Acad Dermatol.* 50:850-853.

Golpon H.A., Fadok V.A., Taraseviciene-Stewart L., Scerbavicius R., Sauer C.,

Welte T., Henson P.M., Voelkel N.F. 2004. Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. *The FASEB Journal.* 18: 1716-1718.

Grimes P.E., Hunt S.G. 1993. Considerations for cosmetic surgery in the black

population. *Clin Plast Surg.* 20(1):27-34.

Guix B., *et al.* 2001. Treatment of keloids by high-dose-rate brachytherapy: a

seven-year study. *Int J Radiat Oncol Biol Phys.* 50:167–172.

Gupta S., Sharma V.K. 2010. Standard guidelines of care: keloids and

hyperthrophic scars. *Indian J Dermatol Venereol Leprol.* 77: 94-100.

Haq M.A., Haq A. 1990. Pressure therapy in treatment of hypertrophic scar, burn

contracture and keloid: The Kenyan experience. *East Afr Med J.* 67:785-793.

- Harting M., Hicks J.M., Levy M. 2008. Dermal Hypertrophies. In : Wolffk, Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller A.S., Leffell D.J., editor. Fitzpatrick's Dermatology in General Medicine, 7th ed. Mc Graw Hill Companies, Inc. 556-558.
- Hochman B., Locali R.F., Matsuoka P.K., Ferreira L.M. 2008. Intralesional triamcinolone acetone for keloid treatment: A systematic review. *Aesth Plast Surg.* 32:705-709.
- Huang C., Murphy G.F., Akaishi S., Ogawa R. 2013. Keloids and hypertrophic scars: Update and future directions. *Plast Reconstr Surg Glob Open.* 1(4): e25.
- Huang L., Cai Y.J., Lung I., Leung B.C.S., Burd A. 2013. A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblast in vitro. *J Plast Reconstr Aesth Surg.* 66: 251-259.
- Huang L., Wong Y.P., Cai Y.J., Lung I., Leung C.S., Burd A. 2010. Low-dose 5-fluorouracil induces cell cycle G2 arrest and apoptosis in keloid fibroblasts. *Br J Dermatol.* 163:1181-1185.
- Kelly A.P. 1991. *Keloids and Hypertrophic scars.* 1st ed. New York; McGraw-Hill, Inc.
- Kelly A.P. 2004. Medical and surgical therapies for keloids. *Dermatol Ther.* 17:212-218.
- Khalifa E.S., Adil A.N., Mahmood R.A. 2014. Debulking of Keloid Combined with Intralesional Injection of 5-Fluorouracil and Triamcinolone Versus

Intralesional Injection of 5-Fluorouracil and Triamcinolone. *Journal of Cosmetics, Dermatological Sciences and Applications*. 4:85-91.

Khan M.A., Bashir M.M., Khan F.A. 2014. Intralesional triamcinolone alone and in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. *J Pak Med Assoc*. 64(9) : 1003-1007.

Kim D.Y., Kim E.S., Eo S.R., Kim K.S., Lee S.Y., Cho B.H. 2005. A surgical approach for earlobe keloid: Keloid fillet flap. *Arch Facial Plast Surg*. 7:172-175.

Kuo Y.R., Wu W.S., Jeng S.F., Wang F.S., Huang H.C., Lin C.Z., *et al.* 2005. Suppressed TGF-beta1 expression is correlated with upregulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. *Lasers Surg Med*. 36:38-44.

Ledon J.A. *et al.* 2013. Intralesional treatment for keloids and hypertrophic scars: a review. *Dermatol Surg*. 39(12): 1745-1757.

Lee J.Y., Yang C.C., Chao S.C., *et al.* 2004. Histopathological differential diagnosis of keloid and hypertrophic scar. *Am J Dermatopathol*. 26:379–384.

Marshall N.J., Goodwin C.J., Holt S.J. 1995. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. *Growth Regul*. 5(2):69-84.

McCoy B.J., Cohen I.K. 1982. Collagenase in keloid biopsies and fibroblasts. *Connect Tissue Res*. 9:181-5.

- Muneuchi G., Suzuki S., Onodera M., Ito O., Hata Y., Igawa H.H. 2006. Long-term outcome of intralesional injection of triamcinolone acetonide for the treatment of keloid scars in Asian patients. *Scand J Plast Reconstr Surg Hand Surg*.40:111-116.
- Mustoe T.A. 2008. Evolution of silicone therapy and mechanism of action in scar management. *Aesthetic Plast Surg*. 32:82-92.
- Mustoe T.A., et al. 2002. International clinical recommendations on scar management. *Plast Reconstr Surg*. 110:560–571.
- Mutalik S. 2005. Treatment of keloids and hypertrophic scars. *Indian J Dermatol Venereol Leprol*. 71:3–8.
- Nanda S., Reddy B.S. 2004. Intralesional 5-fluorouracil as a treatment modality of keloids. *Dermatol Surg*. 30: 54-57.
- Ogawa R., Mitsuhashi K., Hyakusoku H., Miyashita T. 2003. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months. *Plast Reconstr Surg*. 111:547–555.
- Ong C.T., Khoo Y.T., Mukhopadhyay A., Masilamani J., Do D.V., Lim J. 2010. Comparative proteomic analysis between normal skin and keloid scar. *British Journal of Dermatology*. 162:1302-15.
- Peltonen J., Hsiao L.L, Jaakkola S., Sollberg S., Aumailley M., Timpi R. 1991. Activation of Collagen Gene Expression in Keloid : Co-Localization of Type I and VI Collagen and Transforming Growth Factor β 1 mRNA. *J Invest Dermatol*. 97: 240-248.

- Phan T.T., *et al.* 2003. Quercetin inhibits fibronectin production by keloid-derived fibroblasts. Implication for the treatment of excessive scars. *J Dermatol Sci.* 33:192–194.
- Poochareon V.N., Berman B. 2003. New therapies for the management of keloids. *J Craniofac Surg.* 14:654–657.
- Reish R.G., Eriksson E. 2008. Scar treatments: preclinical and clinical studies. *J Am Coll Surg.* 206:719–730.
- Reno F., *et al.* 2003. In vitro mechanical compression induces apoptosis and regulates cytokines release in hypertrophic scars. *Wound Repair Regen.* 11:331–336.
- Robles D.T., Berg D. 2007. Abnormal wound healing : keloids. *Clin Dermatol.* 25: 26-32.
- Rusciani L., Rossi G., Bono R. 1993. Use of cryotherapy in the treatment of keloids. *J Dermatol Surg Oncol.* 19:529-534.
- Satish L., Babu M., Tran, Kien T., Hebda, Patricia A., Wells, A. 2003. Keloid fibroblast responsiveness to epidermal growth factor and activation of downstream intracellular signalling pathways. *Wound Rep Reg.* 12:183-192.
- Shah V.V., Aldahan A.S., Mlacker S., Alsaidan M., Samarkandy S., Nouri K. 2016. 5-Fluorouracil in the Treatment of Keloids and Hypertrophic Scars : A Comparative Review of the Literature. *Dermatol Ther (Heidelb).* 10.1007.

- Sharma S., Bassi R., Gupta A. 2012. Treatment of small keloids with intralesional 5-fluorouracil alone vs. intralesional triamcinolone acetonide with 5-fluorouracil. *J Pakistan Ass Dermatol.* 22: 35-40.
- Slemp A.E., Kirschner R.E. 2006. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. *Curr Opin Pediatr.* 18:396–402.
- Sridharani S.M., Magarakis M., Manson P.N., Singh N.K. Basdag B., Rosson G.D. 2010. The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars. *Annals of Plastic Surgery.* 64:355-361.
- Steifert O., Mrowietz U. 2009. Keloid scarring : bench and bedside. *Arch Dermatol Res.* 301:259-272.
- Stewart C.E., Kim J.Y., Linda I. 2006. Application of mitomycin-C for head and neck keloids. *Otolaryngol Head Neck Surg.* 135:946-950.
- Ulrich D., Ulrich F., Unglaub F., Platkowski A., Palhua N. 2010. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patient with different types of scars and keloids. *J Plast Reconst Aesthet Surg.* 63:1015-1021.
- Urioste S.S., Arndt K.A., Dover J.S. 1999. Keloids and hypertrophic scars : Review and treatment strategies. *Seminars in Cutaneous Medicine and Surgery.* 18(2):159-171.
- Verhaegen P.D., van Zuijlen P.P., Pennings N.M., *et al.* 2009. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar,

and normal skin: an objective histopathological analysis. *Wound Repair*

Regen. 17:649–656.

Wirohadidjojo Y., Dachlan I. 2007. The effect of narrow and broad band ultraviolet B onto keloid fibroblast-VEGF expressions. *Berkala Ilmu Kedokteran.* 39(2).